Magnetic resonance imaging of focal liver lesions: Approach to imaging diagnosis

Hepatology

Volumn 54, Issue 6, 2011, Pages 2227-2237

  Fowler, Kathryn J ^a   Brown, Jeffrey J ^a   Narra, Vamsi R ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; GADOBENATE DIMEGLUMINE; GADOXETIC ACID; HEPATOCYTE NUCLEAR FACTOR 1;

ADENOMA; ARTICLE; BILE DUCT CARCINOMA; BILIARY EXCRETION; BREATH HOLDING; CANCER MORTALITY; CANCER RISK; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; DRUG ELIMINATION; FOCAL LIVER LESION; FOLLOW UP; HEPATOBILIARY RADIOGRAPHY; HEPATOCELLULAR ADENOMA; IMAGE QUALITY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER HEMANGIOMA; METASTASIS; NODULAR HYPERPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PORTAL VEIN; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADENOMA, LIVER CELL; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; FOCAL NODULAR HYPERPLASIA; GADOLINIUM DTPA; HEMANGIOMA; HEPATOCYTES; HUMANS; INCIDENTAL FINDINGS; LIVER; LIVER DISEASES; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MEGLUMINE; ORGANOMETALLIC COMPOUNDS;

EID: 82455168043     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24679     Document Type: Article

References (86)

1. Karhunen PJ. Benign hepatic tumours and tumour like conditions in men. J Clin Pathol 1986; 39: 183-188.
2. Ishak KG, Rabin L. Benign tumors of the liver. Med Clin North Am 1975; 59: 995.
3. Craig J, Peters R, Edmondson H. Tumors of the liver and intrahepatic bile ducts. In: Hartman H, Sobin L, editors. Atlas of Tumor Pathology. Second series, fascicle 26. Washington, DC: Armed Forces Institute of Pathology, 1989.
4. Padia SA, Baker ME, Schaeffer CJ, Remer EM, Obuchowski NA, Winans C, et al. Safety and efficacy of sonographic-guided random real-time core needle biopsy of the liver. J Clin Ultrasound 2009; 37: 138-143.
5. Appelbaum L, Kane RA, Kruskal JB, Romero J, Sosna J. Focal hepatic lesions: US-guided biopsy-lessons from review of cytologic and pathologic examination results. Radiology 2009; 250: 453-458.
6. Whitmire LF, Galambos JT, Phillips VM, Sewell CW, Erwin BC, Torres WE, et al. Imaging-guided percutaneous hepatic biopsy: diagnostic accuracy and safety. J Clin Gastroenterol 1985; 7: 511-515.
7. Xie L, Guang Y, Ding H, Cai A, Huang Y. Diagnostic value of contrast-enhanced ultrasound, computed tomography and magnetic resonance imaging for focal liver lesions: a meta-analysis. Ultrasound Med Biol 2011; 37: 854-861.
8. Wile GE, Leyendecker J. Magnetic resonance imaging of the liver: sequence optimization and artifacts. Magn Reson Imaging Clin N Am 2010; 18: 525-547.
9. Pomfret E, Washburn K, Wald C, Nalesnik M, Douglas D, Russo M, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010; 16: 262-278.
10. Yamada I, Aung W, Himeno Y, Nakagawa T, Shibuya H. Diffusion coefficients in abdominal organs and hepatic lesions: evaluation with intravoxel incoherent motion echo-planar MR imaging. Radiology 1999; 210: 617-623.
11. Kele PG, van der Jagt EJ. Diffusion weighted imaging in the liver. World J Gastroenterol 2010; 16: 1567-1576.
12. Sandrasegaran K, Akisik FM, Lin C, Tahir B, Rajan J, Aisen AM. The value of diffusion-weighted imaging in characterizing focal liver masses. Acad Radiol 2009; 16: 1208-1214.
13. Miller FH, Hammond N, Siddiqi AJ, Schroff S, Khatri G, Wang Y, et al. Utility of diffusion-weighted MRI in distinguishing benign and malignant hepatic lesions. J Magn Reson Imaging 2010; 32: 138-147.
14. Holzapfel K, Bruegel M, Eiber M, Rummeny E, Gaa J. Detection and characterization of focal liver lesions using respiratory-triggered diffusion weighted MR imaging (DWI). Magnetom Flash 2008/2 Siemens.
15. Soyer P, Corno L, Boudiaf M, Aout M, Sirol M, Place V, et al. Differentiation between cavernous hemangiomas and untreated malignant neoplasms of the liver with free-breathing diffusion-weighted MR imaging: comparison with T2-weighted fast spin-echo MR imaging. Eur J Radiol 2010 [Epub ahead of print].
16. Kim T, Murakami T, Takahashi S, Hori M, Tsuda K, Nakamura H. Diffusion-weighted single-shot echo planar MR imaging for liver disease. AJR Am J Roentgenol 1999; 173: 393-398.
17. Kenis C, Deckers F, De Foer B, Van Mieghem F, Van Laere S, Pouillon M. Diagnosis of liver metastases: can diffusion-weighted imaging (DWI) be used as a standalone sequence? Eur J Radiol 2011 [Epub ahead of print].
18. Taouli B, Sandberg A, Stemmer A, Parikh T, Wong S, Xu J, et al. Diffusion-weighted imaging of the liver: comparison of navigator triggered and breathhold acquisitions. J Magn Reson Imaging 2009; 30: 561-568.
19. Bruegel M, Holzapfel K, Gaa J, Woertler K, Waldt S, Kiefer B, et al. Characterization of focal liver lesions by ADC measurements using a respiratory triggered diffusion-weighted single-shot echo-planar MR imaging technique. Eur Radiol 2008; 18: 477-485.
20. Bruegel M, Gaa J, Waldt S, Woertler K, Holzapfel K, Kiefer B, et al. Diagnosis of hepatic metastasis: comparison of respiration-triggered diffusion-weighted echo-planar MRI and five T2-weighted turbo spin-echo sequences. AJR Am J Roentgenol 2008; 191: 1421-1429.
21. Parikh T, Drew SJ, Lee VS, Wong S, Hecht EM, Babb JS, et al. Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. Radiology 2008; 246: 812-822.
22. Holzapfel K, Eiber MJ, Fingerle AA, Bruegel M, Rummeny EJ, Gaa J. Detection, classification, and characterization of focal liver lesions: value of diffusion-weighted MR imaging, gadoxetic acid-enhanced MR imaging and the combination of both methods. Abdom Imaging 2011 [Epub ahead of print].
23. Taouli B, Vilgrain V, Dumont E, Daire JL, Fan B, Menu Y. Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients. Radiology 2003; 226: 71-78.
24. Motosugi U, Ichikawa T, Sano K, Sou H, Onohara K, Muhi A, et al. Double-dose gadoxetic acid-enhanced magnetic resonance imaging in patients with chronic liver disease. Invest Radiol 2011; 46: 141-145.
25. Zech CJ, Vos B, Nordell A, Urich M, Blomqvist L, Breuer J, Reiser MF, et al. Vascular enhancement in early dynamic liver MR imaging in an animal model: comparison of two injection regimen and two different doses of Gd-EOB-DTPA (Gadoxetic acid) with standard Gd-DTPA. Invest Radiol 2009; 44: 305-310.
26. Semelka RC, Brown ED, Ascher SM, Patt RH, Bagley AS, Li W, et al. Hepatic hemangiomas: a multi-institutional study of appearance on T2-weighted and serial gadolinium-enhanced gradient-echo MR images. Radiology 1994; 192: 401-406.
27. Semelka RC, Sofka CM. Hepatic hemangiomas. Magn Reson Imaging Clin N Am 1997: 5: 241-253.
28. Mitsudo K, Watanabe Y, Saga T, Dohke M, Sato N, Minami K, et al. Nonenhanced hepatic cavernous hemangioma with multiple calcifications: CT and pathologic correlation. Abdom Imaging 1995; 20: 459-461.
29. Reimer P, Rummeny EJ, Daldrup HE, Hesse T, Balzer T, Tombach B, et al. Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging. Eur Radiol 1997; 7: 275-280.
30. Ringe KI, Husarik DB, Sirlin CB, Merkle EM. Gadoxetate disodium-enhanced MRI of the liver: part I, protocol optimization and lesion appearance in the non-cirrhotic liver. AJR Am J Roentgenol 2010; 195: 13-28.
31. Quillin SP, Atilla S, Brown JJ, Borrello JA, Yu CY, Pilgram TK. Characterization of focal hepatic masses by dynamic contrast-enhanced MR imaging: findings in 311 lesions. Magn Reson Imaging 1997; 15: 275-285.
32. Kim T, Federle MP, Baron RL, Peterson MS, Kawamori Y. Discrimination of small hepatic hemangiomas from hypervascular malignant tumors smaller than 3 cm with three-phase helical CT. Radiology 2001; 219: 699-706.
33. Leslie DF, Johnson CD, Johnson CM, Ilstrup DM, Harmsen WS. Distinction between cavernous hemangiomas of the liver and hepatic metastases on CT: value of contrast enhancement patterns. AJR Am J Roentgenol 1995; 164: 625-629.
34. Li KC, Glazer GM, Quint LE, Francis IR, Aisen AM, Ensminger WD, et al. Distinction of hepatic cavernous hemangioma from hepatic metastases with MR imaging. Radiology 1988; 169: 409-415.
35. Whitney WS. Dynamic breath-hold multiplanar spoiled gradient-recalled MR-imaging with gadolinium enhancement for differentiating hepatic hemangiomas from malignancies at 1.5-T. Radiology 1993; 189: 863-870.
36. Doo KW, Lee CH, Choi JW, Kim KA, Park CM. "Pseudo Washout" sign in high-flow hepatic hemangioma on gadoxetic acid contrast-enhanced MRI mimicking hypervascular tumor. AJR Am J Roentgenol 2009; 193: W490-W496.
37. Tamada T, Ito K, Yamamoto A, Sone T, Kanki A, Tanaka F, Higashi H. Hepatic hemangiomas: evaluation of enhancement patterns at dynamic MRI with gadoxetate disodium. AJR Am J Roentgenol 2011; 196: 824-830.
38. Hussain SM, Terkivatan T, Zondervan PE, Langouw E, de Rave S, Ifzermans FNM, et al. Focal nodular hyperplasia: findings at state-of-the-art MR imaging, US, CT, and pathologic analysis. Radiographics 2004; 24: 3-19.
39. Zech CJ, Grazioli L, Breuer J, Reiser MF, Schoenberg SO. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Investig Radiol 2008; 43: 504-511.
40. Marin D, Brancatelli G, Federle MP, Lagalla R, Catalano C, Passariello R, et al. Focal nodular hyperplasia: typical and atypical MRI findings with emphasis on the use of contrast media. Clin Radiol 2008; 63: 577-585.
41. Morana G, Grazioli L, Schneider G, Testoni M, Menni K, Chiesa A, et al. Hypervascular hepatic lesions: dynamic and late enhancement pattern with Gd-BOPTA. Acad Radiol 2002; 9: S476-S479.
42. Grazioli L, Morana G, Federle MP, Brancatelli G, Testoni M, Kirchin MA, et al. Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine. Radiology 2001; 221: 731-739.
43. Morana G, Grazioli L, Kirchin MA, Bondioni MP, Faccioli N, Guarise A, et al. Solid hypervascular liver lesions: accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after gadobenate dimeglumine administration. Invest Radiol 2011; 46: 225-239.
44. Graziolo, L, Morana G, Kirchin MA, Schneider G. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 2005; 236: 166-177.
45. Park Y, Kim SH, Kim SH, Jeon YH, Lee J, Kim MJ, et al. Gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI versus gadobenate dimeglumine (Gd-BOPTA)-enhanced MRI for preoperatively detecting hepatocellular carcinoma: an initial experience. Korean J Radiol 2010; 11: 433-440
46. Huppertz A, Haraida S, Kraus A, Zech CJ, Scheidler J, Breuer J, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MRI: correlation with histopathologic findings and spiral CT. Initial observations. Radiology 2005; 234: 468-478.
47. Ni Y, Marchal G, Yu J, Muhler A, Lukito G, Baert AL. Prolonged positive contrast enhancement with Gd-EOB-DTPA in experimental liver tumors: potential value in tissue characterization. J Magn Reson Imaging 1994; 4: 355-363.
48. Ni Y, Marchal G. Enhanced magnetic resonance imaging for tissue characterization of liver abnormalities with hepatobiliary contrast agents: an overview of preclinical animal experiments. Top Magn Reson Imaging 1998; 9: 183-195.
49. Fujita M, Yamamoto R, Fritz-Zieroth B, Yamanaka T, Takahashi M, Miyazawa T, et al. Contrast enhancement with Gd-EOB-DTPA in MR imaging of hepatocellular carcinoma in mice: a comparison with superparamagnetic iron oxide. J Magn Reson Imaging 1996; 6: 472-477.
50. Fujita M, Yamamoto R, Takahashi M, Tsuji T, Yamanaka T, Miyazawa T, et al. Paradoxic uptake of Gd-EOB-DTPA by hepatocellular carcinoma in mice: quantitative image analysis. J Magn Reson Imaging 1997; 7: 768-770.
51. Narita M, Hatano E, Arizono S, Miyagawa-Hayashino A, Isoda H, Kitamura K, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinomas. J Gastroenterol 2009; 44: 793-798.
52. Bioulac-Sage P, Laumonier H, Couchy G, Le Bail B, Sa Cunha A, Rullier A, et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. HEPATOLOGY 2009; 50: 481-489.
53. Bioulac-Sage P, Rebouissou S, Thomas C, Blanc J, Saric J, Sa Cunha A, et al. Hepatocellular adenoma subtype classification on using molecular markers and immunohistochemistry. HEPATOLOGY 2007; 46: 740-748.
54. Zucman-Rossi J, Jeannot E, Nhieu JT, Scoazec JY, Guettier C, Rebouissou S, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. HEPATOLOGY 2006; 43: 515-524.
55. Van der Borght S, Libbrecht L, Katoonizadeh A, Aerts R, Nevens F, Verslype C, et al. Nuclear beta-catenin staining and absence of steatosis are indicators of hepatocellular adenomas with an increased risk of malignancy. Histopathology 2007; 51: 855-856.
56. Laumonier H, Bioulac-Sage P, Laurent C, Zucman-Rossi J, Balabaud C, Trillaud H. Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. HEPATOLOGY 2008; 48: 808-818.
57. Ronot M, Bahrami S, Calderaro J, Valla D, Bedossa P, Belghti J, et al. Hepatocellular adenomas: accuracy of magnetic resonance imaging and liver biopsy in subtype classification. HEPATOLOGY 2011; 53: 1182-1191.
58. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
59. Kelekis NL, Semelka RC, Worawattanakul S, de Lange EE, Ascher SM, Ahn IO, et al. Hepatocellular carcinoma in North America: a multi institutional study of appearance on T1-weighted, T2-weighted, and serial gadolinium-enhanced gradient echo images. AJR Am J Roentgenol 1998; 170: 1005-1013.
60. Marrero JA, Hussain HK, Nghiem HV, Umar R, Fontana RJ, Lok AS. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl 2005; 11: 281-289.
61. Kudo M. Multistep human hepatocarcinogenesis: correlation of imaging with pathology. J Gastroenterol 2009; 44: 112-118.
62. Carlos RC, Kim HM, Hussain HK, Francis IR, Nghiem HV, Fendrick AM. Developing a prediction rule to assess hepatic malignancy in patients with cirrhosis. Am J Roentgenol 2003; 180: 893-900.
63. Khan AS, Hussain HK, Johnson TD, Weadock WJ, Pelletier SJ, Marrero JA. Value of delayed hypointensity and delayed enhancing rim in magnetic resonance imaging diagnosis of small hepatocellular carcinoma in the cirrhotic liver. J Magn Reson Imaging 2010; 32: 360-366.
64. Cruite I, Schroeder M, Merkle EM, Sirlin CB. Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver. AJR Am J Roentgenol 2010; 195: 29-41.
65. Kawada N, Ohkawa K, Tanaka S, Matsunaga T, Uehara H, Ioka T, et al. Improved diagnosis of well-differentiated hepatocellular carcinoma with gadolinium ethoxybenzyl diethylene triamine pentaacetic acid-enhanced magnetic resonance imaging and Sonazoid contrast-enhanced ultrasonography. Hepatol Res 2010; 40: 930-936.
66. Mita K, Kim SR, Kudo M, Imoto S, Nakajima T, Ando K, et al. Diagnostic sensitivity of imaging modalities for hepatocellular carcinoma smaller than 2 cm. World J Gastroeneterol 2010; 16: 4187-4192.
67. Di Martino M, Marin D, Guerrisi A, Baski M, Galati F, Rossi M, et al. Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the detection of hepatocellular carcinoma in patients with cirrhosis. Radiology 2010; 256: 806-816.
68. Raman SS, Leary C, Bluemke D, Amendola M, Sahani D, McTavish J, et al. Improved characterization of focal liver lesions with liver-specific gadoxetic acid disodium-enhanced magnetic resonance imaging: a multicenter phase 3 clinical trial. J Comput Assist Tomogr 2010; 34: 163-172.
69. Sun HY, Lee JM, Shin CI, Lee DH, Moon SK, Kim KW, et al. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (<2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol 2010; 45: 96-103.
70. Motosugi U, Ichikawa T, Sou H, Sano K, Tominaga L, Muhi A, et al. Distinguishing hypervascular pseudolesions of the liver form hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Radiology 2010; 256: 152-158.
71. Saito K, Kotake F, Ito N, Ozuki T, Mikami R, Abe K, et al. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci 2005; 4: 1-9.
72. Tsuda N, Okada M, Murakami T. New proposal for the staging of nonalcoholic steatohepatitis: evaluation of liver fibrosis on Gd-EOB-DTPA enhanced MRI. Eur J Radiol 2010; 73: 137-142.
73. Organ distribution: allocation of livers-liver transplant candidates with HCC. UNOS website:
74. American College of Radiology (ACR): LI-RADS: liver imaging reporting and data systems. ACR website: Version1.0_March2011
75. Bolondi L, Gaiani S, Celli N, Golfieri R, Grigioni W, Leoni S, et al. Chracterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. HEPATOLOGY 2005; 42: 27-34.
76. Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso J, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. HEPATOLOGY 2008; 47: 97-104.
77. Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 2005; 25: 133-142.
78. Welzel T, Graubard B, El-Serag H, Shaib Y, Hsing A, Davila J, et al. Risk factors for intra- and extrahepatic cholangiocarcinoma in the United States: a population based case-control study. Clin Gastroenterol Hepatol 2007; 5: 1221-1228.
79. Maetani Y, Itoh K, Watanabe C, Shibata T, Ametani F, Yamabe H, et al. MR imaging of intrahepatic cholangiocarcinoma with pathologic correlation. AJR Am J Roentgenol 2001; 176: 1499-1507.
80. Chung YE, Kim MJ, Park YN, Choi JY, Pyo JY, Kim YC, et al. Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation. Radiographics 2009; 29: 683-700.
81. Hamrick-Turner J, Abbitt PL, Ros PR. Intrahepatic cholangiocarcinoma: MR appearance. AJR Am J Roentgenol 1992; 158: 77-79
82. Fan ZM, Yamashita Y, Harada M, Baba Y, Yamamoto H, Matsukawa T, et al. Intrahepatic cholangiocarcinoma: spin-echo and contrast-enhanced dynamic MR imaging. AJR Am J Roentgenol 1993; 161: 313-317
83. Murakami T, Nakamura H, Tsuda K, Ishida T, Tomoda K, Hori S, et al. Contrast-enhanced MR imaging of intrahepatic cholangiocarcinoma: pathologic correlation study. J Magn Reson Imaging 1995; 5: 165-170.
84. Vilgrain V, Van Beers BE, Flejou JF, Belghiti J, Delos M, Gautier AL, et al. Intrahepatic cholangiocarcinoma: MRI and pathologic correlation in 14 patients. J Comput Assist Tomogr 1997; 21: 59-65
85. Zech CJ, Herrmann KA, Reiser MF, Schoenberg SO. MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA. Magn Reson Med Sci 2007; 6: 43-52.
86. Hammerstingl R, Huppertz A, Breuer J, Balzer T, Blakeborough A, Carter R, et al. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal lesions. Eur Radiol. 2008; 18: 457-467.